Article
Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.
American journal of respiratory and critical care medicine - 1 Oct 2002
Sharma Surendra K, Balamurugan Arumugam, Saha Pradip Kumar, Pandey Ravindra M, Mehra Narinder K
Abstract excerpt
Though several risk factors for the development of hepatotoxicity due to antituberculosis drugs have been suggested, involvement of genetic factors is not fully established. We have studied the major histocompatibility complex (MHC) class II alleles and clinical risk factors for the development of hepatotoxicity in 346 North Indian patients with tuberculosis undergoing antituberculosis treatment. Of these, 56...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
